- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.03. | Rare diseases: Novartis' Fabhalta recommended by CHMP for C3 glomerulopathy | ||
| 03.03. | Rare diseases: CHMP recommends Krystal's Vyjuvek for dystrophic epidermolysis bullosa | ||
| 03.03. | Key clinical trial trends - EU vs US perspectives | ||
| 28.02. | Rare Disease Day 2025 - highlighting recent approvals in the rare disease space | ||
| 28.02. | Researchers discover previously unidentified genes linked to rare diseases | ||
| 28.02. | Defying the odds: speeding patient access to life-changing treatments in rare disease | ||
| 27.02. | Eli Lilly unveils plans to invest $27bn in four new US manufacturing sites | ||
| 27.02. | EC approves Celltrion's RoActemra biosimilar Avtozma for inflammatory diseases | ||
| 27.02. | Why local knowledge is key to global pharmacovigilance outcomes | ||
| 26.02. | Amgen's Blincyto recommended by NICE for new adult leukaemia indication | ||
| 26.02. | AstraZeneca's camizestrant shows promise in phase 3 breast cancer study | ||
| 26.02. | J&J's shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial | ||
| 26.02. | NHS England appoints Sir James Mackey as CEO | ||
| 26.02. | DE&I in clinical trials: the role of health literacy and AI | ||
| 25.02. | FDA approves Mirum's Ctexli as first treatment for rare lipid storage disease CTX | ||
| 25.02. | NICE recommends pharmaand's Rubraca for advanced ovarian cancer | ||
| 25.02. | Recce's topical gel shows promise in acute bacterial skin and skin structure infections | ||
| 25.02. | Porterhouse Medical appoints Michael Tague as president of Porterhouse Medical US | ||
| 25.02. | Class is the missing link in health equity strategies | ||
| 24.02. | PMLiVE's Top Pharma list is live | ||
| 24.02. | Gilead's seladelpar granted conditional EC approval to treat rare liver disease PBC | ||
| 24.02. | Standing out in a crowded precision oncology landscape | ||
| 21.02. | EC approves Biocon's Stelara biosimilar Yesintek for inflammatory diseases | ||
| 21.02. | BMS shares overall survival results for Opdivo in phase 3 lung cancer trial | ||
| 21.02. | Why patients ignore your trials - how to make clinical trials stand out in the real world among the world's biggest brands |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
